[1]Kong FM,Ten Haken RK,Schipper MJ,et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study[J]. Int J Radiat Oncol Biol Phys,2005,63(2):324-333.DOI: 10.1016/j.ijrobp.2005.02.010. [2]Palma DA,Senan S,Tsujino K,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys,2013,85(2): 444-450.DOI: 10.1016/j.ijrobp.2012.04.043. [3]Yano H,Hamanaka R,Nakamura M,et al. Smad,but not MAPK,pathway mediates the expression of type I collagen in radiation induced fibrosis[J]. Biochem Biophys Res Commun,2012,418(3):457-463.DOI:10.1016/j.bbrc.2012.01.039. [4]Dong XM,Yin RH,Yang Y,et al. GATA-2 inhibits transforming growth factor-β signaling pathway through interaction with Smad4[J]. Cell Signal,2014,26(5):1089-1097.DOI:10.1016/j.cellsig.2014.01.028. [5]Zhao L,Wang L,Ji W,et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan[J]. Int J Radiat Oncol Biol Phys,2009,74(5):1385-1390.DOI: 10.1016/j.ijrobp.2008.10.065. [6]Kim JY,Kim YS,Kim YK,et al. The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients[J/OL]. Radiat Oncol,2009,4:59[2014-05-20].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789091/.DOI:10.1186/1748-717X-4-59. [7]Anscher MS,Kong FM,Andrews K,et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis[J]. Int J Radiat Oncol Biol Phys,1998,41(5):1029-1035.DOI:无. [8]Fu XL,Huang H,Bentel G,et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta[J]. Int J Radiat Oncol Biol Phys,2001,50(4):899-908.DOI:无. [9]De Jaeger K,Seppenwoolde Y,Kampinga HH,et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2004,58(5):1378-1387.DOI: 10.1016/j.ijrobp.2003.09.078. [10]Stenmark MH,Cai XW,Shedden K,et al. Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy[J]. Int J Radiat Oncol Biol Phys,2012,84(2):217-222.DOI:10.1016/j.ijrobp.2012.03.067. [11]Ao X,Zhao L,Davis MA,et al. Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice[J/OL]. J Hematol Oncol,2009,2:6[2014-05-20].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663566/.DOI:10.1186/1756-8722-2-6. [12]Wang D,Zhu J,Sun J,et al. Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy[J]. Clin Transl Oncol,2012,14(12):943-952.DOI:10.1007/s12094-012-0890-3. [13]Yuan X,Liao Z,Liu Z,et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy[J]. J Clin Oncol,2009,27(20):3370-3378.DOI:10.1200/JCO.2008.20.67. [14]Wang L,Bi N. TGF-beta1 gene polymorphisms for anticipating radiation-induced pneumonitis in non-small-cell lung cancer: different ethnic association[J]. J Clin Oncol,2010,28(30):621-622.DOI: 10.1200/JCO.2010.31.0458. [15]Voets AM,Oberije C,Struijk RB,et al. No association between TGF-beta1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients[J]. Radiother Oncol,2012,105(3):296-298.DOI:10.1016/j.radonc.2012.09.016. [16]Yuan ST,Ellingrod VL,Schipper M,et al. Genetic variations in TGFbeta1,tPA,and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer[J]. J Thorac Oncol,2013,8(2):208-213.DOI: 10.1097/JTO.0b013e318274592e. [17]Kelsey CR,Jackson L,Langdon S,et al. A polymorphism within the promoter of the TGFbeta1 gene is associated with radiation sensitivity using an objective radiologic endpoint[J]. Int J Radiat Oncol Biol Phys,2012,82(2):247-255.DOI:10.1016/j.ijrobp.2011.02.064. [18]Yin M,Liao Z,Liu Z,et al. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy[J]. Cancer,2012,118(2):528-535.DOI: 10.1002/cncr.26214. [19]Yang M,Zhang L,Bi N,et al. Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy[J]. Int J Radiat Oncol Biol Phys,2011,79(5):1402-1407.DOI: 10.1016/j.ijrobp.2009.12.042. [20]Pang Q,Wei Q,Xu T,et al. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2013,85(5):1332-1339.DOI:10.1016/j.ijrobp.2012.10.011. [21]Zhang J,Li B,Ding X,et al. Genetic variants in inducible nitric oxide synthase gene are associated with the risk of radiation-induced lung injury in lung cancer patients receiving definitive thoracic radiation[J]. Radiother Oncol,2014,111(2):194-198.DOI:10.1016/j.radonc.2014.03.001. [22]Hildebrandt MA,Komaki R,Liao Z,et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer[J/OL]. PLoS One,2010,5(8):e12402[2014-05-20].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928273/.DOI:10.1371/journal.pone.0012402. [23]Kerns SL,de Ruysscher D,Andreassen CN,et al. STROGAR-strengthening the reporting of genetic association studies in radiogenomics[J]. Radiother Oncol,2014,110(1):182-188.DOI:10.1016/j.radonc.2013.07.011. [24]Ramella S,Trodella L,Mineo TC,et al. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage ⅡIA-B NSCLC treated with combined-modality therapy[J]. Int J Radiat Oncol Biol Phys,2010,76(1):110-115.DOI:10.1016/j.ijrobp.2009.01.036. [25]王静,王平,庞青松,等.非小细胞肺癌三维适形放疗放射性肺损伤临床及剂量学因素分析[J].中华放射肿瘤学杂志,2009,18(6):448-451.DOI:10.3760/cma.j.issn.1004-4221.2009.06.448. [26]付和谊,卢冰,徐冰清,等.Ⅲ+Ⅳ期非小细胞肺癌三维适形放疗正常肺V5、V10预测放射性肺损伤前瞻性临床研究[J].中华放射肿瘤学杂志,2009,18(6):439-444.DOI:10.3760/cma.j.issn.1004-4221.2009.06.439. [27]Valentini V,Massaccesi M,Balducci M,et al. Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?[J]. Int J Radiat Oncol Biol Phys,2010,76(2):535-539.DOI: 10.1016/j.ijrobp.2009.02.075. [28]Wang D,Sun J,Zhu J,et al. Functional dosimetric metrics for predicting radiation-induced lung injury in non-small cell lung cancer patients treated with chemoradiotherapy[J/OL]. Radiat Oncol,2012,7:69[2014-05-20].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434088/.DOI:10.1186/1748-717X-7-69. [29]Hoover DA,Reid RH,Wong E,et al. SPECT-based functional lung imaging for the prediction of radiation pneumonitis: a clinical and dosimetric correlation[J]. J Med Imaging Radiat Oncol,2014,58(2):214-222.DOI: 10.1111/1754-9485.12145. [30]Vinogradskiy Y,Tucker SL,Bluett JB,et al. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates[J]. J Thorac Oncol,2012,7(11):1676-1682.DOI:10.1097/JTO.0b013e318269410a.
2015, Vol. 24 
